Potential Benefits of Urolithin A
Urolithin A has demonstrated biological activity in people and has produced encouraging results in selected muscle and cellular outcomes. The evidence is not yet strong enough to support broad anti-ageing, disease-prevention or energy claims.
1. Mitochondrial health
Evidence label: Human biomarker evidence
The 2019 first-in-human trial established that oral Urolithin A was absorbed and reported a favourable safety profile over the study period. Four weeks at 500 mg or 1,000 mg changed plasma acylcarnitines and skeletal-muscle mitochondrial gene expression.[2]
Later trials reported effects on plasma metabolites, inflammation-related markers and muscle proteins associated with mitophagy.[4,5]
What this supports
- Urolithin A reaches the circulation after oral administration.
- It can influence molecular and metabolic markers related to mitochondrial biology.
- The proposed mitophagy mechanism has some translational support in people.
What this does not support
- that everyone has “damaged mitochondria” needing supplementation;
- that a biomarker change produces more day-to-day energy;
- that Urolithin A prevents a mitochondrial disease;
- that it reverses biological age.
Evidence verdict
Biological activity is supported; the size and practical importance of the benefit remain uncertain.
2. Muscle Function
Evidence label: Human clinical evidence
In the 2022 JAMA Network Open trial, 66 adults aged 65 to 90 received 1,000 mg Urolithin A or placebo daily for four months. The trial did not find significant between-group improvements in its primary outcomes — six-minute walk distance and maximal ATP production in the hand muscle. Secondary outcomes measuring repeated muscle contractions showed improvements in endurance in hand and leg muscles, and several plasma biomarkers changed.[4]
Consumer interpretation
The result is neither a failure nor proof of a broad performance benefit. It suggests a possible effect on local muscle endurance while showing that the intervention did not outperform placebo on the principal walking and ATP outcomes.
Evidence verdict
Promising for selected endurance tests, but primary whole-body outcomes were not significantly improved.
Muscle strength and physical performance
Evidence label: Human clinical evidence
A 2022 randomised, double-blind study included 88 middle-aged adults who were overweight and generally insufficiently active. Participants received placebo, 500 mg or 1,000 mg daily for four months. The study reported improvements in certain muscle-strength measures with Urolithin A, and the 1,000 mg group improved some exercise-performance outcomes. Muscle samples also showed changes in proteins linked with mitophagy.[5]
Important limitations include the moderate sample size, multiple outcomes and the sponsor’s commercial interest in the ingredient. The trial does not show that Urolithin A treats sarcopenia or that it provides the same benefit in young, active or medically frail populations.
Evidence verdict
Encouraging, but confirmation in larger independent trials is needed.
Exercise performance and recovery
Evidence label: Early human evidence
Research has expanded into athletic populations:
- An eight-week randomised study in 20 resistance-trained men reported improvements in selected endurance, strength, inflammation, oxidative-stress and protein-metabolism measures.[8]
- A 2025 study in highly trained male distance runners reported recovery-related molecular changes, reduced markers of muscle damage, lower perceived exertion and increased aerobic capacity, but no additional improvement in running performance.[9]
Small samples, male-only populations and specialised training backgrounds limit generalisation.
Evidence verdict
Not established as an ergogenic aid. Recovery findings are preliminary.
3. Healthy Aging
Inflammation
Evidence label: Human biomarker evidence
Several studies reported changes in C-reactive protein, cytokines or metabolic markers associated with inflammation.[4-7] The 2024 systematic review described a possible dose-related anti-inflammatory effect across five human studies.[6]
Inflammatory biomarkers vary naturally and are not interchangeable with prevention or treatment of an inflammatory disease.
Evidence verdict
Some biomarker evidence; no general anti-inflammatory treatment claim is justified.
Immune ageing
Evidence label: Early human evidence
In 2025, 50 healthy middle-aged adults were randomised to 1,000 mg daily or placebo for four weeks. The study reported changes in less terminally exhausted, naive-like CD8+ T cells, CD8+ fatty-acid oxidation, selected natural-killer and monocyte populations, and exploratory gene-expression patterns.[7]
The study did not test whether participants experienced fewer infections, better vaccine responses, reduced cancer risk or improved clinical outcomes.
Evidence verdict
Interesting mechanistic evidence, not proof of stronger immunity.
Healthy ageing and longevity
Evidence label: Not established in humans
The 2016 preclinical paper reported extended lifespan in C. elegans, a microscopic worm, and improved selected muscle outcomes in rodents.[1] These findings helped justify human research, but they do not show that Urolithin A extends human life.
The 2024 systematic review concluded that further research is required to determine effects on human healthspan and lifespan.[6]
Evidence verdict
No evidence that Urolithin A extends human lifespan or reverses ageing.
Brain, heart, cancer and metabolic disease
Evidence label: Mainly laboratory and animal evidence
A large preclinical literature investigates Urolithin A in models of neurodegeneration, cardiovascular disease, cancer, inflammatory conditions and metabolic dysfunction. These studies can identify mechanisms and research directions. They do not justify consumer claims that a supplement prevents or treats these diseases.
4. Skin appearance and cosmetic use
Evidence label: Preprint and laboratory evidence
A 2023 preprint described laboratory findings and randomised topical studies using creams or a skincare regimen containing Urolithin A. The authors reported changes in measures related to wrinkles, skin structure and UVB-induced redness.[10]
Because the clinical report has not completed peer review in the source reviewed for this pack, because finished formulations contain multiple components, and because independent replication is limited, the appropriate consumer wording is:
It should not be described as repairing DNA, reversing skin ageing or treating sun damage.
Evidence verdict
Promising but early; peer-reviewed, independent finished-product trials are needed.
Urolithin A is an emerging cosmetic ingredient being investigated for effects on skin appearance and cellular ageing pathways.
Benefits summary
| Research area | Current consumer conclusion |
| Absorption and biological activity | Supported in short human studies |
| Mitophagy and mitochondrial markers | Supported at biomarker/mechanistic level |
| Muscle endurance | Some positive secondary outcomes; mixed overall |
| Muscle strength | Encouraging findings in one middle-aged trial |
| Whole-body physical performance | Inconsistent |
| Athletic performance | Not established |
| Immune ageing | Early biomarker evidence |
| Skin appearance | Preliminary, including a preprint |
| Human longevity | Not demonstrated |
| Disease prevention or treatment | Not demonstrated and not a suitable supplement claim |